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1 regulatory T cells (Tregs) and difficulties in the identification and isolation of such cells are major obstacles in the study of human Tregs. The availability of human Treg-like cell lines is likely to facilitate a better understanding of the molecular basis of Treg function and aid the discovery of pharmacological reagents to regulate Treg activity in a disease state. In this study, we examined the Treg phenotype and the immune suppressive effect of a human T-cell leukemia virus type 1 (HTLV-1) infected cell line, MT-2. The results clearly demonstrated that the MT-2 cell line has the phenotypic and functional characteristics of human Tregs and is a useful tool in the study of human Tregs.
The MT-2 cell line was derived from normal human cord leukocytes of a healthy donor by co-cultivation with leukemic cells from an adult T-cell leukemia (ATL) patient. 1 It has been shown that MT-2 cells express FoxP3, and when mixed at a ratio of 1 : 2 (suppressors/responders), MT-2 cells inhibited the proliferative response of purified human peripheral blood (PB) CD4 1 CD25 2 cells stimulated with dendritic cells and anti-CD3 Ab. 2 However, the Treg phenotypic markers and relative suppressive activity of MT-2 cells on both proliferation and cytokine production of cocultured responder cells need to be further evaluated.
HUMAN TREG-LIKE PHENOTYPIC MARKERS EXPRESSED BY MT-2 CELLS
First, we examined the expression of Treg phenotypic markers on MT-2 cells. As shown in Figure 1a , MT-2 cells expressed CD4; however, unlike human PB CD4 T cells, MT-2 cells did not express CD3. CD25 was expressed by human PB CD4 cells at low levels compared with mouse CD4 cells, and only highly expressing CD25 (CD25 high ) human cells had consistent suppressive function. 3 By contrast, all MT-2 cells expressed high levels of CD25. We confirmed the previous observation 2 that 4 We and others reported that TNFR2 was preferentially expressed by ,40% of mouse Tregs 5 and by a majority of human PB CD4 
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1 Tregs. 6 Only a small fraction of MT-2 cells expressed low levels of TNFR2, which is similar to the TNFR2 expression pattern of mouse Tregs but not human Tregs. All MT-2 cells expressed high levels of GITR on the surface, and the majority of them expressed CTLA-4, a potential effector molecule of Tregs. It has been shown that approximately one-third of human Tregs expressed HLA-DR; HLA-DR 1 Tregs represented a distinct functional subset of Tregs responsible for contactdependent suppression. 7 Interestingly, more than half of the MT-2 cells expressed HLA-DR. In addition, MT-2 cells expressed high levels of CCR4, a chemokine receptor recently found to enhance viability and maintain a high frequency of Tregs in patients with HTLV-1 infection, as well as directing Tregs to the tumor environment. MT-2 cells were negative for CD45RA and expressed high levels of CD45RO, suggesting that they may be an 'effector/memory' type human Treg-like cells.
SUPPRESSIVE ACTIVITY OF MT-2 CELLS ON PRIMARY HUMAN PB CD4 CELLS AND MOUSE CD4 CELLS
We next examined the number of MT-2 cells required to inhibit cocultured human PB CD4 cells. As shown in Figure 1b , the proliferative responses of PB CD4 cells to TCR stimulation, as measured by CFSE dilution, were suppressed by 9.7%, 31.6%, 63.3% and 91.2% after the addition of MT-2 cells at ratios of 10 : 1, 10 : 2, 10 : 5 and 10 : 10 (PB CD4 cells/MT-2 cells), respectively. Because the MT-2 cells alone produced high levels of IFN-c and TNF, but not IL-17A (data not shown), we used IL-17A as an indicator to examine the suppressive effect of MT-2 cells on the cytokine production of cocultured human primary CD4 cells. As shown in Figure 1c , MT-2 cells potently inhibited IL-17A production over a ratio of 10 : 1 to 10 : 10 (CD4/MT-2 cells, P,0.05).
We then investigated whether the suppressive function of MT-2 cells was allogeneic in manner. We used mouse CD4 cells as responder cells to examine the suppressive effect of MT-2 cells. As shown in Figure 1d , at a ratio of 10 : 5 to 10 : 10 (CD4/MT-2 cells), MT-2 cells inhibited the proliferation of cocultured mouse CD4 cells by 8% and 51.9%, respectively. However, at a 10 : 1 ratio, MT-2 cells stimulated, to a limited extent, the proliferation of cocultured mouse CD4 cells (P.0.05); this was probably caused by an allostimulatory effect of MT-2 cells. Similarly, IFN-c production by mouse CD4 cells was markedly inhibited by MT-2 cells when cocultured at a ratio of 10 : 5 and 10 : 10 (CD4/MT-2, P,0.05-0.01), but not at a ratio of 10/1 (P.0.05, Figure 1e ). Although MT-2 cells also suppressed TNF and IL-17 production by mouse CD4 cells (data not shown), they did not suppress IL-2 production (data not shown).
HTLV-1 INFECTION IS NOT SUFFICIENT TO CONFER THE TREG PHENOTYPE AND FUNCTION OF MT-2 CELLS
To exclude the possibility that the suppressive activity of MT-2 cells was exerted by transferring HTLV-1 virus to responder cells, we compared MT-2 cells with HTLV-1-infected MS-9 cells because both of them can infect or transform other T cells in vitro. 8, 9 As shown in Figure 1f and g, MT-2 cells consistently showed suppressive activity, whereas MS-9 cells did not suppress the proliferation of cocultured primary human CD4 cells. Furthermore, unlike MT-2 cells, MS-9 cells did not express the characteristic Treg molecules such as FoxP3 and CTLA-4 (Figure 1h ), although they expressed CD25 (data not shown). These data indicate that infection by HTLV-1 is not sufficient to confer the phenotypic and functional attributes of Tregs, and the suppressive activity of MT-2 cells is not based on its release of infectious HTLV-1. CTLA-4 is expressed by MT-2 cells but not by MS-9 cells, suggesting a role of CTLA-4 in mediating the suppressive activity of MT-2 cells. Nevertheless, MT-2 cells have the potential to produce TGF-b; 10 this immunosuppressive cytokine may also contribute to the suppressive activity of MT-2 cells.
Taken together, our data suggest that MT-2 cells have the phenotypic and functional characteristics of human Tregs and therefore may be used as a human Treg-like cell line for Treg studies. Similar to human Tregs, MT-2 cells were CD4 1 CD25
hi FoxP3 1 and expressed CTLA-4, GITR, CCR4, HLA-DR, CD-45RO and TNFR2 but not CD127. The expression levels of these molecules on MT-2 cells are readily manipulated by molecular biological techniques, which may help reveal the roles of these molecules on the biological function of Tregs. The suppressive activity of MT-2 cells can be conveniently monitored with a CFSE dilution-based proliferation assay or with cytokine levels by using normal human PB CD4 cells or normal mouse CD4 cells as responders. Our data also revealed some differences between MT-2 cells and primary human Tregs. These differences should be taken into account when using MT-2 cells as a cellular model to study human Tregs. Nevertheless, MT-2 cells can be used as a positive control for human Treg studies and for biochemical studies of Tregs, which require larger numbers of cells.
